Technical Field
[0001] The present disclosure relates to a patch for the alleviation and prevention of acne,
and more particularly to the novel use of a biodegradable metal containing magnesium
as a main component.
Background Art
[0002] Thorough research into microneedles has been carried out since 1998 when Prausnitz
and associates at Georgia Tech in the United States made a microneedle array with
a silicon device using semiconductor-processing technology and suggested the possibility
of application thereof to drug delivery. When a microneedle is inserted into the skin,
sufficiently high physical strength thereof has to be maintained so that the microneedle
may be inserted without being bent or broken, and thus properties enabling shape control
and strength suitable therefor are required. In order to satisfy these properties,
stainless steel has been used as the material for a microneedle, but in the case in
which small particles thereof are left behind in the body, there is a problem of inflammation,
and in the case of polymers (PLA, PGA, biodegradable copolymer), there is a problem
in that penetration does not occur.
[0003] Korean Patent Application Publication No.
2016-0058261 discloses a water-soluble microneedle made of a material such as polyglycolide (PGA),
polylactide-glycolide copolymer (PLGA), hyaluronic acid, alginic acid, pectin, etc.
and a method of manufacturing the same, Korean Patent No.
1622388 discloses a silicon microneedle stamp and a method of manufacturing the same, and
Korean Patent Application Publication No.
2015-0121053 discloses a microneedle made of a material such as silicon, silicon dioxide, ceramics,
metals (stainless steel, titanium, nickel, molybdenum, chromium, cobalt, etc.) and
synthetic or natural resins and coated with a Japanese encephalitis vaccine antigen.
[0004] As described above, the microneedle developed to date is an alternative drug administration
means capable of replacing a drug delivery mode through oral administration or a drug
delivery mode through injection, and has been used as a device, namely a kind of drug
carrier, capable of delivering a drug through the epidermis without stimulating nociceptive
nerves distributed throughout the skin.
[0005] Meanwhile, Korean Patent Application Publication No.
2017-0115449 filed and laid open by the present applicant discloses a microneedle using a biodegradable
metal and a patch including the same. Here, it has been confirmed that the microneedle
is useful as a drug carrier and is also effective at reducing wrinkles when used alone
due to the action thereof as a mineral.
Disclosure
Technical Problem
[0006] An objective of the present disclosure is to provide the novel use of a biodegradable
metal, which is the main component of a microneedle conventionally developed as a
drug delivery means.
[0007] In particular, the present disclosure confirms that a biodegradable metal, which
has been used as the main component of a microneedle, exhibits antibacterial activity
when used alone against an acne pathogen, even without the need to additionally include
a drug, and is intended to provide the novel use of a specific biodegradable metal
for the alleviation and prevention of acne.
Technical Solution
[0008] The present disclosure provides a patch for the alleviation and prevention of acne,
including a biodegradable metal represented by Chemical Formula 1 below and having
an anti-acne effect.
[Chemical Formula 1] Mg
aZn
bX
c
[0009] In Chemical Formula 1, a, b and c are wt% of individual components, a+b+c = 100 wt%,
0≤a≤100, 0≤b≤100, and 0≤c≤10, among which a or b is the greatest, and X is at least
one selected from the group consisting of Ca, Fe, Mn, Si, Na, Zr, Ce, and P.
[0010] In such a patch for the alleviation and prevention of acne, the biodegradable metal
may be provided in the form of a microneedle or a thin plate.
[0011] In the patch for the alleviation and prevention of acne according to a preferred
embodiment of the present disclosure, the biodegradable metal may be represented by
Chemical Formula 1, in which a, b and c are wt% of individual components, a+b+c =
100 wt%, i) 90≤a≤100, 0≤b≤10, and 0≤c≤10 or ii) 0≤a≤10, 90≤b≤100, and 0≤c≤10, and
X is at least one selected from the group consisting of Ca, Fe, Mn, Si, Na, Zr, Ce,
and P.
[0012] In the patch for the alleviation and prevention of acne according to the most preferred
embodiment, the biodegradable metal may be Mg having a purity of 95% or more and containing
inevitable impurities.
[0013] In the patch for the alleviation and prevention of acne according to an embodiment
of the present disclosure, the biodegradable metal may include two or more metal phases
to form a galvanic circuit to thus accelerate a degradation rate. Such a biodegradable
metal may include an Mg
2Ca phase, an MgZn phase or a Ca
2Mg
6Zn
3 phase.
[0014] In the patch for the alleviation and prevention of acne according to an embodiment
of the present disclosure, the biodegradable metal may be configured such that the
surface of the metal is coated with a second metal of a different type in order to
form a galvanic circuit. Here, the second metal may be at least one metal selected
from the group consisting of sodium, magnesium, potassium, iron, nickel, zinc, gallium,
selenium, strontium, zirconium, molybdenum, niobium, tantalum, titanium, silicon,
silver, gold, manganese, and calcium.
[0015] Another embodiment of the present disclosure provides a method of using the patch
for the alleviation and prevention of acne as described above, including attaching
the patch to skin suffering from acne.
[0016] In the method according to a preferred embodiment, a moisturizing step or a skin-soothing
step may be performed before attaching the patch to the skin suffering from acne.
Advantageous Effects
[0017] According to the present disclosure, a patch using a biodegradable metal has antibacterial
activity against an acne pathogen when used alone, without the need to additionally
load a drug, so it is useful for the alleviation and prevention of acne. Through the
simple method in which the patch is manufactured in various forms and is applied to
the skin, the patch of the present disclosure can be effective at preventing acne
or alleviating the generated acne.
Brief Description of Drawings
[0018]
FIG. 1 is an exploded view of a microneedle obtained by subjecting a sheet made of
a biodegradable metal to microneedle processing;
FIG. 2 schematically shows a microneedle obtained by subjecting the processed microneedle
to bending;
FIG. 3 schematically shows a tip-type microneedle and a microneedle holder;
FIG. 4 is a photograph (A) showing a microneedle prototype according to the present
disclosure and a photograph (B) showing the bendability thereof;
FIG. 5 is photographs showing a microneedle patch according to the present disclosure
(A: before use, B: after use) ;
FIG. 6 is a photograph showing microneedle samples according to the present disclosure
provided for an antimicrobial test;
FIGS. 7 to 9 are photographs showing antibacterial or antifungal test results, FIG.
7 showing the results of a test on Propionibacterium acnes ATCC 6919, FIG. 8 showing the results of a test on Staphylococcus epidermidis ATCC 12228, and FIG. 9 showing the results of a test on Trichophyton rubrum ATCC 28188;
FIGS. 10 and 11 schematically show various shapes of the microneedle patch according
to the present disclosure;
FIG. 12 is photographs showing the results of sensory evaluation using the microneedle
patch according to the present disclosure, in detail, showing the skin condition before
attachment (left), state of attachment (center), and the skin condition 8 hours after
attachment (right);
FIG. 13 is a photograph showing the microneedle patch according to the present disclosure
attached to a test subject in a clinical trial;
FIG. 14 is an image showing a test site in which the facial region is divided into
6 sections for acne severity assessment according to the global acne grading system
(GAGS) in a clinical trial;
FIG. 15 is a table showing the unique factor of each section shown in FIG. 14 and
the global score in the acne severity assessment according to the global acne grading
system (GAGS) in a clinical trial;
FIG. 16 is a table that categorizes the presence and severity of adverse reactions
in the skin irritation evaluation in a clinical trial; and
FIG. 17 is photographs taken throughout the test period after attachment of a magnesium
microneedle patch to a test subject in a clinical trial.
Best Mode
[0019] Acne is a chronic inflammatory disease of the pilosebaceous unit, and causes various
skin changes such as comedones (hardened sebum in the hair follicles), papules (raised
skin lesions less than 1 cm in size), pustules, nodules, pseudocysts, etc., and thus
concave scars or enlarged scars may be left as sequelae thereof. Acne occurs concentratedly
on the face, neck, chest and the like where sebaceous glands are gathered, and is
a disease in which the sebaceous glands attached to the hair follicles that form hair
are inflamed.
[0020] The exact cause of acne has not been identified, but acne is deemed to occur due
to multiple causes in combination rather than a single cause. The major cause thereof
is that, during puberty, secretion from the sebaceous glands is vigorous due to an
excess of male hormones and the epithelium of the hair follicles causes dyskeratosis
(abnormal keratinization showing incomplete and immature keratinization), and the
hair follicles are blocked, forming comedones, which are the basic lesions of acne.
[0021] In acne development caused by bacteria, a known pathogen of acne is
Propionibacterium acnes, among microorganisms residing in the hair follicles. This acne pathogen is the main
cause of troubles while eating and growing sebum. In normal people, even though such
bacteria are present on the skin, no problems occur, but in the case in which the
hair follicles are blocked and sebum accumulates in the hair follicles, such bacteria
eat sebum and grow rapidly.
[0022] Moreover, this acne pathogen excretes a fatty acid that is a substance similar to
butter after eating fat (triglyceride). Such a chemical change causes the healthy,
weakly acidic skin to become alkalized due to the pH imbalance of oil thereon, resulting
in deterioration of the skin's own function and creating a vicious cycle that further
harms the skin. In order to prevent and alleviate acne caused by
Propionibacterium acnes, therapeutic methods using applicable drugs or edible drugs have been commonly proposed.
[0023] Meanwhile, a microneedle using a biodegradable metal was developed by the present
applicant and filed (Korean Patent Application Publication No.
2017-0115449).
[0024] In the present disclosure, based on the results of thorough research into the microneedle
thus developed, it has been confirmed that the corresponding biodegradable metal exhibits
antibacterial activity against the acne pathogen
Propionibacterium acnes, and thus novel use of the biodegradable metal is devised.
[0025] In the present disclosure, the description in connection with the biocompatible metal,
the method of manufacturing the same in a microneedle form, and a series of metallic
reactions occurring on the skin follows Korean Patent Application Publication No.
2017-0115449.
[0026] However, in the present disclosure, it is found that the biodegradable metal is not
limited only to the use as a microneedle for a drug carrier, but acts alone as a functional
configuration having antibacterial activity against the acne pathogen.
[0027] In the present disclosure, a biodegradable metal using magnesium or zinc alone or
in a combination with a metal of a different type such as calcium, etc. is manufactured
in the form of a thin plate or a microneedle, and the antibacterial activity thereof
against an acne pathogen is evaluated. As a result, it is confirmed that the biodegradable
metal manufactured using magnesium, calcium, or zinc alone or an alloy thereof with
a metal of a different type in a specific amount has antibacterial activity when used
alone, even without the need to additionally include a drug.
[0028] Accordingly, an aspect of the present disclosure pertains to a patch for the alleviation
and prevention of acne including a biodegradable metal represented by Chemical Formula
1 below and having an anti-acne effect.
[Chemical Formula 1] Mg
aZn
bX
c
[0029] In Chemical Formula 1 a, b and c are wt% of individual components, a+b+c = 100 wt%,
0≤a≤100, 0≤b≤100, and 0≤c≤10, among which a or b is the greatest, and X is at least
one selected from the group consisting of Ca, Fe, Mn, Si, Na, Zr, Ce, and P.
[0030] It is preferred that the biodegradable metal contain mainly magnesium or zinc. Therefore,
in Chemical Formula 1, a, b and c are wt% of individual components, a+b+c = 100 wt%,
i) 90≤a≤100, 0≤b≤10, and 0≤c≤10 or ii) 0≤a≤10, 90≤b≤100, and 0≤c≤10, and X is at least
one selected from the group consisting of Ca, Fe, Mn, Si, Na, Zr, Ce, and P.
[0031] The biodegradable metal according to the present disclosure is a metal that is attached
to or inserted into the subcutaneous or epithelial region and then absorbed and degraded
to thus release metal ions and degradation products into the body. Magnesium (Mg),
calcium (Ca), zinc (Zn), etc., which are alkaline-earth-metal-based biodegradable
metals, have a mechanism for releasing hydrogen gas by reacting with water, as represented
in Schemes 1 to 3 below.
[Scheme 1] Mg + 2H
2O → Mg(OH)
2 + H
2 (gas)
Scheme 2] Ca + 2H
2O → Ca(OH)
2 + H
2 (gas)
[Scheme 3] Zn + 2H
2O → Zn(OH)
2 + H
2 (gas)
[0032] In the present disclosure, it is preferred that the biodegradable metal be composed
exclusively of magnesium (Mg), zinc (Zn), etc. In particular, in view of exhibiting
superior biocompatibility and non-toxicity in normal cells or tissues, a biodegradable
metal composed of magnesium alone is most preferable. Here, the magnesium alone or
zinc alone refers to pure magnesium or zinc having a purity of 95% or more and containing
inevitable impurities generated in the metal production process.
[0033] In addition, the biodegradable metal may be manufactured using two or more metals
to accelerate the degradation rate thereof in the subcutaneous or epithelial region,
that is, to form a galvanic circuit. In the present disclosure, the biodegradable
metal may be configured such that the surface of the biodegradable metal represented
by Chemical Formula 1 may be coated with a second metal of a different type in order
to form a galvanic circuit. Here, examples of the second metal may include, but are
not limited to, sodium, magnesium, potassium, iron, nickel, zinc, gallium, selenium,
strontium, zirconium, molybdenum, niobium, tantalum, titanium, silicon, silver, gold,
manganese, calcium, etc. In particular, chromium or nickel must not be included when
iron (Fe) is included.
[0034] In the patch for the alleviation and prevention of acne according to the present
disclosure, the biodegradable metal may be provided in the form of a thin plate or
a microneedle. For example, the microneedle may be manufactured through a typical
method of manufacturing a soluble microneedle in the industry, such as laser cutting,
sheet metal processing, casting, etching, etc., and the manufacturing method thereof
is not particularly limited. For example, as shown in FIG. 1, a thin-plate-type sheet
10 made of a biodegradable metal is manufactured, formed into a certain shape using
a laser cutting machine (marking machine), and then bent using a jig press, thereby
manufacturing a microneedle.
[0035] In the present disclosure, the patch containing such a biodegradable metal may be
used alone for the purpose of alleviating and preventing acne, without the need to
additionally apply or load a drug.
[0036] FIG. 2 schematically shows a microneedle 11 obtained by subjecting the processed
microneedle to bending in order to penetrate the skin.
[0037] The microneedle according to the present disclosure may be provided in an integrated
form, or may be configured to include a microneedle 20 and a microneedle holder 21,
as shown in FIG. 3. In the microneedle using the microneedle holder 21, needles may
be deliberately left behind in the subcutaneous region by applying distortion after
the needles are inserted.
[0038] FIG. 4 is a photograph (A) showing a microneedle prototype manufactured according
to an embodiment of the present disclosure and a photograph (B) showing the bendability
thereof.
[0039] According to the present disclosure, in order to facilitate application of the microneedle
to the skin, the microneedle may be manufactured in the form of a patch.
[0040] As shown in FIG. 5, the microneedle patch is used to fix the microneedle to the skin,
and includes a microneedle and a patch unit formed on the surface of the microneedle
opposite the surface on which needles are provided. There is no particular limitation
on the size, shape, and material of the patch unit. As shown in FIG. 5B, the microneedle
that is used may be discolored due to ionization in the subcutaneous region.
[0041] When the patch including the biodegradable metal according to the present disclosure
is applied to the skin, it may exhibit an anti-acne effect when used alone, without
the need to additionally include or apply a drug. In order to further increase the
above effect or shorten the onset time of the effect, it is preferred that a moisturizing
step or skin-soothing step be performed before attaching the patch of the present
disclosure. Here, the moisturizing step may be performed through application of various
moisturizing cosmetics, for example, toner or moisturizing mist, etc., and the skin-soothing
step may be performed through application of functional cosmetics or medicines known
to alleviate skin redness or acne, but the present disclosure is not limited thereto.
[0042] The moisturizing step or the skin-soothing step merely serves to assist the anti-acne
effect of the patch including the biodegradable metal according to the present disclosure,
and it is not required for this step to be first performed in order for the effect
of the patch of the present disclosure to be realized.
[0043] The present disclosure aims to develop the novel use of the biodegradable metal in
the form of a microneedle for the alleviation and prevention of acne. This use is
intended to be confirmed through the following examples in a manner in which the activity
of the biodegradable metal sample against various microorganisms present on the skin
is evaluated and selective activity thereof against only the acne pathogen is exhibited.
Mode for Disclosure
[0044] A better understanding of the present disclosure will be given through the following
examples, and these examples are not to be construed as limiting the scope of the
present disclosure.
<Example 1>
[0045] In order to evaluate the anti-acne activity of the biodegradable metal according
to the present disclosure, samples were provided to the Korea Testing & Research Institute,
and antibacterial and antifungal tests were performed in the following manner.
[0046] The samples that were provided were sheets (having a thickness of 100 µm) manufactured
using pure Mg (magnesium having a purity of 95% or more) containing inevitable impurities
generated during the manufacture thereof, and were cut to a predetermined size and
used as test samples, as shown in FIG. 6.
<Test devices and materials>
(1) Test devices
[0047]
Autoclave (Coretech, Korea)
Dry oven (Jisico, Korea)
Water bath (Polyscience, USA)
Incubator (Memmert, Germany)
pH meter (Thermo Orion, USA)
Stop watch (Time Art, Japan)
Vortex mixer (Thermolyne, USA)
Container (Iwaki Pyrex, Japan)
Sterile pipette (Falcon, USA)
Petri dish (SPL, Korea)
Volumetric flask (Myung Sung, Korea)
Mechanical shaker (Jisico, Korea)
Clean bench (Sugong Yanghaeng, Korea)
Colony counter (Deokwoo Science, Korea)
Anaerobic container (DIFCO, USA)
(2) Test materials
1) Test strain
[0048] Obtained from Korean Culture Center of Microorganisms
- Propionibacterium acnes ATCC 6919
- Staphylococcus epidermidis ATCC 12228
- Trichophyton rubrum ATCC 28188
2) Medium and reagent
[0049]
- Reinforced clostridial medium broth (DIFCO, USA)
- Brain Heart Infusion broth (DIFCO, USA)
- Sabouraud dextrose broth (DIFCO, USA)
- Reinforced clostridial medium agar (DIFCO, USA)
- Tryptic soy agar (DIFCO, USA)
- Sabouraud dextrose agar (DIFCO, USA)
- Gaspak™ EZ (DIFCO, USA)
- 0.05 % polysorbate 80 solution
- Sterile liquid paraffin
(3) Test method
1) Test method
a. Preculture of test pathogen and preparation
[0050] P. acnes was inoculated into a reinforced clostridial medium (RCM) broth and cultured for
3 days at (35±1)°C. The cultured pathogen solution was inoculated into a new RCM broth
and cultured under the same conditions as above, and this procedure was repeated once
more. Anaerobic conditions were maintained using sterile liquid paraffin throughout
the process of culturing the strain. Thereafter, the resulting culture solution was
used as a test pathogen solution.
[0051] S. epidermidis was inoculated into a Brain Heart Infusion broth, cultured at (35±1)°C for (18 to
24) hours, and then used as a test pathogen solution.
[0052] T. rubrum was inoculated into a Sabouraud dextrose agar and cultured at (25±1)°C for 14 days.
A 0.05% polysorbate 80 solution was dispensed on a solid medium in which the test
pathogen was grown, and the spores were separated using a spreader and then passed
through gauze to remove the hyphae. The spore solution thus prepared was adjusted
to (1 to 9) x 10
7 CFU/mL and then used as a test pathogen solution.
b. Test procedure
[0053] Each pathogen culture solution was evenly inoculated onto the previously prepared
reinforced clostridial medium (RCM) agar, tryptic soy agar and Sabouraud dextrose
agar using a sterile cotton swab, and the prepared sample (20 mm x 20 mm) was placed
on the center of the medium. Thereafter,
P. acnes was cultured at (35±1)°C for 5 days under anaerobic conditions,
S. epidermidis was cultured at (35±1)°C for (24±2) hours, and
T. rubrum was cultured at (25±1)°C for 7 days. Thereafter, the test was performed by measuring
the zone of inhibition around the sample.
2) Results
[0054] The width W of the zone of inhibition was calculated using Equation 1 below.
W: width of zone of inhibition (mm)
T: total diameter of sample and zone of inhibition (mm)
D: diameter of sample (mm)
[Table 1]
| Test strain |
T |
D |
W |
| P. acnes |
32 |
20 |
6.0 |
| S. epidermidis |
20 |
20 |
0.0 |
| T. rubrum |
20 |
20 |
0.0 |
[0055] As summarized in Table 1 above, based on the results of the antibacterial effect
on
P. acnes, the total diameter T of the sample and the zone of inhibition was 32 mm, and the
diameter D of the sample was observed to be 20 mm. Therefore, the width W of the zone
of inhibition was determined to be 6.0 mm using the above calculation equation (FIG.
7).
[0056] Based on the results of the antibacterial effect on
S. epidermidis, the total diameter T of the sample and the zone of inhibition was 20 mm, and the
diameter D of the sample was observed to be 20 mm. Therefore, the width W of the zone
of inhibition was determined to be 0.0 mm using the above calculation equation (FIG.
8).
[0057] Based on the results of the antifungal effect on T.
rubrum, the total diameter T of the sample and the zone of inhibition was 20 mm, and the
diameter D of the sample was 20 mm. Therefore, the width W of the zone of inhibition
was determined to be 0.0 mm using the above calculation equation (FIG. 9).
[0058] The widths of the zones of inhibition of
P. acnes, S. epidermidis and
T. rubrum by the sample [referred to as Mg Micro Carrier Multi Care] under the present test
conditions were 6.0 mm, 0.0 mm and 0.0 mm, respectively.
[0059] Consequently, the biodegradable metal of the present disclosure had antibacterial
activity against only the acne pathogen, and antibacterial or antifungal effects against
the other pathogens were not observed.
<Example 2> Manufacture of microneedle and patch
[0060] The same biodegradable metal sheet as the sheet provided for the evaluation of the
antibacterial activity of Example 1 was manufactured, after which a microneedle was
manufactured using a laser marking machine (JTY FIBER MA20, JTW system). Here, the
tip angles of the microneedle were 15°, 30° and 35°, and the needle heights were 0.5
mm, 1.0 mm and 1.5 mm.
[0061] A microneedle patch was manufactured by attaching a hydrocolloid patch coated with
an adhesive to the surface of the microneedle opposite the surface on which needles
were formed. The microneedle patch thus manufactured was packaged and sterilized.
[0062] Such a microneedle patch may be manufactured in various shapes for the alleviation
and prevention of acne, and examples thereof are illustrated in FIGS. 10 and 11.
[0063] The microneedle patch thus obtained was attached after facial washing to any one
of acne sites of seven 15-year-old boys with skin suffering from acne, and then the
acne alleviation effect was observed for 7 days.
[0064] With regard to the evaluation criteria, the case in which the acne treatment effect
is remarkable, that is, the case in which the area of skin suffering from acne is
clearly reduced and the extent of acne inflammation is also clearly reduced, is awarded
a score of 5, the case in which the extent of such alleviation is moderate is awarded
a score of 4, the case in which the extent of such alleviation is mild is awarded
a score of 3, the case in which there is no change is awarded a score of 2, and the
case in which the acne is worsened is awarded a score of 1, after which comprehensive
judgment was made based on the total score, and the results thereof are shown in Table
2 below.
[Table 2]
| |
Subject 1 |
Subject 2 |
Subject 3 |
Subject 4 |
Subject 5 |
Subject 6 |
Subject 7 |
Total score |
| Microneedle patch of the present disclosure |
5 |
5 |
5 |
4 |
4 |
5 |
4 |
32 |
[0065] As is apparent from Table 2, it can be found that the evaluation results of the majority
of subjects corresponded to a score of 5, indicating that the microneedle patch of
the present disclosure has a notable effect on the alleviation of acne.
[0066] Meanwhile, FIG. 12 shows the skin condition (left) before attachment of the microneedle
patch to the subject having acne on the forehead, the state of attachment (center),
and the skin condition (right) 8 hours after attachment, indicative of the immediate
acne alleviation effect 8 hours after attachment of the microneedle patch of the present
disclosure.
<Example 3> Clinical trial
[0067] In order to evaluate whether the biodegradable metal of the present disclosure is
suitable for use on skin suffering from acne, a clinical evaluation was performed
in the following manner by the Chungcheongbuk-do Global Cosmeceutical Center.
(1) Test method
[0068] A test was carried out on adult males and females aged 18 to 40 years. The test product
was used once a day on the test site in accordance with the prescribed method of use,
and the effect thereof was observed through visual evaluation. The evaluation was
carried out in accordance with the Center's internal guidelines (SOP), and, with regard
to matters not specified in the Ministry of Food and Drug Safety notification, reference
was made to the References cited herein. The test site was the facial portion of the
test subject.
[0069] The prescribed method of use was as follows.
① After thoroughly washing the face, tidy up the skin.
② Remove the cap of a syringe containing a high-concentration Centella ampoule (having
a moisturizing or soothing effect).
③ Drop an appropriate amount of the high-concentration Centella ampoule on the microcarrier
of a magnesium patch (made of magnesium having a purity of 95% or more).
④ Remove a protective film without touching the magnesium patch.
⑤ Before bedtime, closely attach the patch to the treatment location, and then press
the patch several times so as to stimulate the skin.
⑥ The next morning, remove the patch.
⑦ Attach a hydrocolloid band to the location from which the patch was removed and
keep it there throughout the day.
[0070] An example of applying the magnesium patch to the test subject is shown in FIG. 13.
[0071] The test was performed by selecting 20 persons as test subjects who met the selection
criteria and to whom the exclusion criteria did not apply.
[0072] After selecting test subjects suitable for the study in accordance with the selection
and exclusion criteria, the skin condition of the test subjects was observed, and
visual evaluation and photography (VISIA-CR) were performed before product use (0
day), 1 day after product use, 3 days after product use, 4 days after product use,
and 5 days after product use.
(2) Measurement and evaluation method
1) Preparation step
[0073] For the evaluation, the test subjects were stabilized for 30 minutes in a waiting
room under constant-temperature and constant-humidity conditions (22±2°C, 40-60% RH)
such that the skin surface temperature and humidity were adapted to the environment
of the measurement space. For objective measurement, device evaluation was performed
by one researcher at the same site every time measurement and visual evaluation was
performed by two researchers.
2) Photographing
[0074] The entire face of each subject was photographed using a facial imaging system (VISIA-CR,
Canfield, USA) equipped with a camera (Canon, EOS6D, JAPAN), and a Standard 2 measurement
mode was used therefor. The facial imaging system (VISIA-CR, Canfield) was used in
the state in which the forehead and chin of the test subject were fixed in order to
minimize the subject's movement, and a gray card was used therewith to correct for
changes in light levels upon photographing. Measurement was performed before product
use (0 day), 1 day after product use, 3 days after product use, and 5 days after product
use. The overlay function was used to photograph the same site, and only images were
utilized in the present study.
3) Visual evaluation
[0075] The visual evaluation was performed through a double-blind test by two experts.
[0076] When there was a difference in the evaluation between the two experts, the suitability
was evaluated by selecting the lower level, and the adverse skin reaction was evaluated
by selecting the higher level.
[0077] The visual evaluation was performed through the global acne grading system (GAGS).
In GAGS, the face, chest, and back regions were divided into 6 sections depending
on the surface-area distribution and density of the pilosebaceous units, a unique
factor was assigned to each section, and a local score was assigned at the lesion
site, and applied to the global score, followed by grading and evaluation. The six
sections are as shown in FIG. 14.
[0078] Moreover, the unique factor of each section and the global score are as shown in
FIG. 15.
4) Survey evaluation
[0079] A survey was performed on the test product's general evaluation (sensation of use),
change evaluation after use, satisfaction therewith, adverse reactions, etc. by each
test subject upon the visit (5 days after product use).
a. Global assessment of efficacy
[0080] A survey was performed in a manner in which the test subjects directly answered a
questionnaire on the measurement items after using the test product according to five
levels: very satisfied (5), satisfied (4), neutral (3), dissatisfied (2), and very
dissatisfied (1). The researcher determined the efficacy of the test product by representing,
as a percentage, the number of test subjects providing each answer.
b. Survey assessment of product preference
[0081] A survey was performed in a manner in which the test subjects directly answered a
questionnaire on the test product and the sensation of use thereof. The evaluation
items, particularly the general evaluation (sensation of use) and the satisfaction
with the product, were evaluated according to five levels: very satisfied (5), satisfied
(4), neutral (3), dissatisfied (2), and very dissatisfied (1).
5) Evaluation of compliance
[0082] From the date of start of product use to the end thereof, whether or not the product
was applied and whether or not an adverse reaction occurred were recorded in a daily
compliance log.
6) Evaluation of skin irritation
[0083] Whether adverse reactions such as erythema, edema, scaling, itching, stinging, burning,
tightness, prickling or other adverse reactions were caused by the test product was
closely observed, and when the skin exhibited an adverse reaction, the grade was marked
depending on the severity thereof and test opinions therefor were recorded. If the
subject should become unable to participate in the test even when it is not the day
of the subject visit, the subject was required to complete the "Agreement to renounce
test participation" with signature attached.
[0084] The table that categorizes the presence and severity of adverse reactions is shown
in FIG. 16.
(3) Analysis of results
1) Visual evaluation
[0085] The visual evaluation results were obtained by comparing the difference before and
after product use, and the evaluation method was based on the method described in
3) of (2) above.
2) Statistical analysis
[0086] Changes after product use were evaluated using a paired t-test and statistical results
were regarded as statistically significant when the significant difference was 5%
(p <0.05), which is the most frequently used in biological statistical analysis.
3) Survey evaluation
[0087] The evaluation was based on the results of a survey assessment on efficacy and product
preference.
[0088] 4) The statistical analysis program that was used was SPSS version 10.0 software.
(4) Results
[0089] The test subjects who participated in the present human application test were 20
healthy adult males and females with an average age of 21.9±2.9 years, and all 20
subjects who participated in the test completed the final test without dropping out.
1) Results of visual evaluation
[0090] Based on the results of visual evaluation, it was confirmed that the evaluation grade
through the global score decreased from moderate to mild in some test subjects, and
the evaluation grade through the global score by all of the test subjects was mild,
indicating that there was no significant change.
[0091] Meanwhile, the test product showed a statistically significant difference at each
of 1 day after product use, 3 days after product use, and 5 days after product use
compared to before product use (day 0) (p <0.05).
[0092] During the evaluation period, adverse effects on the skin due to the test product
did not occur, and the analysis results thereof are shown in Table 3 below.
[Table 3]
| Measurement time |
Before product use (day 0) |
1 day after product use |
3 days after product use |
5 days after product use |
| Grade |
Mild |
Mild |
Mild |
Mild |
| Visual evaluation (mean ± standard deviation, unit: Score) |
17.7±3.3 |
16.3±4.0 |
15.9±3.6 |
15.4±4.2 |
| p-value |
- |
0.005 (p < 0.05) |
0.012 (p < 0.05) |
0.003 (p < 0.05) |
2) Survey results
a. Survey results for assessment of efficacy
[0093] The results of a survey conducted on the measurement items after use of the test
product are shown in Table 4 below.
[Table 4]
| |
Number of test subjects (percentage, %) |
Mean |
Standard deviation |
| *5 |
*4 |
*3 |
*2 |
*1 |
| Acne alleviation effect |
6 (30.0) |
14 (70.0) |
0 (0.0) |
0 (0.0) |
0 (0.0) |
4.3 |
0.5 |
| Note) 5: very satisfied, 4: satisfied, 3: neutral, 2: dissatisfied, 1: very dissatisfied |
[0094] Based on the results of survey evaluation, the acne alleviation effect item was evaluated
to be 'satisfied' or more by 100% of the test subjects.
b. Survey results for assessment of preference
[0095] The preference felt by the test subjects for satisfaction with the product after
product use, the sensation of use, and the change after use was surveyed. The results
thereof are shown in Table 5 below.
[Table 5]
| |
Number of test subjects (percentage, %) |
Mean |
Standard deviation |
| *5 |
*4 |
*3 |
*2 |
*1 |
| Product color |
12 (60.0) |
7 (35.0) |
1 (5.0) |
0 (0.0) |
0 (0.0) |
4.6 |
0.6 |
| Product viscosity |
12 (60.0) |
7 (35.0) |
1 (5.0) |
0 (0.0) |
0 (0.0) |
4.6 |
0.6 |
| Extent of stimulation |
6 (30.0) |
9 (45.0) |
5 (25.0) |
0 (0.0) |
0 (0.0) |
4.1 |
0.8 |
| Extent of skin absorption |
6 (30.0) |
8 (40.0) |
5 (25.0) |
1 (5.0) |
0 (0.0) |
4.0 |
0.9 |
| Adhesion |
6 (30.0) |
7 (35.0) |
6 (30.0) |
1 (5.0) |
0 (0.0) |
3.9 |
0.9 |
| Softness |
5 (25.0) |
12 (60.0) |
3 (15.0) |
0 (0.0) |
0 (0.0) |
4.1 |
0.6 |
| Moisturizing effect |
7 (35.0) |
6 (30.0) |
7 (35.0) |
0 (0.0) |
0 (0.0) |
4.0 |
0.9 |
| Sebum reduction effect |
4 (20.0) |
14 (70.0) |
2 (10.0) |
0 (0.0) |
0 (0.0) |
4.1 |
0.6 |
| (Note) 5: very satisfied, 4: satisfied, 3: neutral, 2: dissatisfied, 1: very dissatisfied |
[0096] Based on the results of survey evaluation, the color and viscosity items with regard
to the satisfaction with the product were evaluated to be 'neutral' or more by 100%
of the test subjects. With regard to the sensation of use, the extent of stimulation
was evaluated to be 'neutral' or more by 100% of the test subjects, and the extent
of skin absorption and adhesion were evaluated to be 'neutral' or more by 95% of the
test subjects. In addition, with regard to the change after use, softness, moisturization,
and sebum reduction effect were evaluated to be 'neutral' or more by 100% of the test
subjects.
3) Evaluation of skin irritation
[0097] The results of evaluation of skin irritation (self-evaluation) on the test subjects
are shown in Table 6 below.
[Table 6]
| |
Erythema |
Edema |
Scaling |
Itching |
Stinging |
Burning |
Tightness |
Prickling |
| 1 day after use |
No |
No |
No |
No |
No |
No |
No |
No |
| 3 days after use |
No |
No |
No |
No |
No |
No |
No |
No |
| 5 days after use |
No |
No |
No |
No |
No |
No |
No |
No |
[0098] The test subjects were to report to the researcher immediately upon the occurrence
of adverse reactions. Also, whether skin irritation occurred was marked on the questionnaire.
During the present test, based on the results of questionnaire survey by the test
subjects, no adverse reactions on the skin by the test product were observed in any
of the test subjects.
[0099] Moreover, even in the visual evaluation by the researcher, adverse skin reactions
were not observed.
4) Photographing results
[0100] All of the test subjects were photographed, and not all are shown herein, and only
some are illustrated in FIG. 17.
[0101] As shown in FIG. 17, the shape of the magnesium patch used as the test material or
the form of attachment thereof were confirmed, from which the basis of visual observation
of the acne alleviation effect can be found.
[0102] The skin irritation evaluation and skin penetration effects of the microneedle and
the microneedle patch for acne alleviation and prevention according to the present
disclosure have been proven through the experiments of Korean Patent Application Publication
No.
2017-0115449 filed and laid open by the present applicant. Thereby, the patch including the biodegradable
metal of the present disclosure does not show toxicity in normal cells or tissues
and can penetrate the skin without irritation to the skin, ultimately exhibiting antibacterial
activity against the acne pathogen, which can contribute to simple and safe acne alleviation
and prevention.
[0103] Also, the major cause of the selective anti-acne activity of the patch including
the non-toxic biodegradable metal having high biocompatibility is assumed to be the
locally increased pH due to the generation of OH
- ions in the process of degradation of the metal, as represented in Schemes 1 to 3.
When pure magnesium or pure zinc metal includes the components of Chemical Formula
1 to thus accelerate the degradation rate thereof, a more rapid antibacterial effect
is expected.
Industrial Applicability
[0104] The patch using the biodegradable metal of the present disclosure has antibacterial
activity when used alone against an acne pathogen without the need to additionally
load a drug, and is useful for the alleviation and prevention of acne. Through a simple
method in which the patch is manufactured in various forms and is applied to the skin,
the patch of the present disclosure can be useful for the prevention of acne or the
alleviation of generated acne.
1. A patch for alleviation and prevention of acne, comprising a biodegradable metal represented
by Chemical Formula 1 below and having an anti-acne effect:
[Chemical Formula 1] MgaZnbXc
in Chemical Formula 1, a, b and c are wt% of individual components, a+b+c = 100 wt%,
0≤a≤100, 0≤b≤100, and 0≤c≤10, among which a or b is greatest, and X is at least one
selected from the group consisting of Ca, Fe, Mn, Si, Na, Zr, Ce, and P.
2. The patch of claim 1, wherein the biodegradable metal is provided in a form of a microneedle.
3. The patch of claim 1, wherein the biodegradable metal is provided in a form of a thin
plate.
4. The patch of claim 1, wherein, in Chemical Formula 1, a, b and c are wt% of individual
components, a+b+c = 100 wt%, i) 90≤a≤100, 0≤b≤10, and 0≤c≤10 or ii) 0≤a≤10, 90≤b≤100,
and 0≤c≤10, and X is at least one selected from the group consisting of Ca, Fe, Mn,
Si, Na, Zr, Ce, and P.
5. The patch of claim 1, wherein the biodegradable metal is Mg having a purity of 95%
or more and containing inevitable impurities.
6. The patch of claim 1, wherein the biodegradable metal comprises two or more metal
phases to form a galvanic circuit to thus accelerate a degradation rate.
7. The patch of claim 6, wherein the biodegradable metal comprises an Mg2Ca phase.
8. The patch of claim 6, wherein the biodegradable metal comprises an MgZn phase.
9. The patch of claim 6, wherein the biodegradable metal comprises a Ca2Mg6Zn3 phase.
10. The patch of claim 1, wherein the biodegradable metal is configured such that a surface
of the metal is coated with a second metal of a different type.
11. The patch of claim 10, wherein the second metal is at least one metal selected from
the group consisting of sodium, magnesium, potassium, iron, nickel, zinc, gallium,
selenium, strontium, zirconium, molybdenum, niobium, tantalum, titanium, silicon,
silver, gold, manganese, and calcium.
12. A method of using the patch of any one of claims 1 to 11, comprising attaching the
patch to skin suffering from acne.
13. The method of claim 12, wherein a moisturizing step or a skin-soothing step is performed
before attaching the patch to the skin suffering from acne.